Hillhurst Biopharmaceuticals

Hillhurst Biopharmaceuticals is pioneering the oral delivery of therapeutic gases through its GLASS technology platform, moving beyond traditional inhalation methods. Founded in 2018, the company has advanced into clinical stages, with a Phase 2a trial cleared for its Parkinson's disease candidate and a pipeline targeting sickle cell disease and acute pain. It is a privately held, pre-revenue company backed by non-dilutive grant funding from foundations and government sources, led by a team with deep experience in hematology, commercialization, and drug development.

GLASS (Medical Gas in Liquid Advanced Stability System) - a proprietary platform for stabilizing and delivering therapeutic gases via oral liquid formulations.

Competition includes existing inhaled gas therapies and other companies developing novel delivery methods for gases or alternative mechanisms for the same indications. Hillhurst's differentiation hinges on the convenience and potential pharmacokinetic advantages of its oral liquid format, but it must compete with established standards of care and other innovative modalities in development.